BERLIN (Reuters) -CureVac will withdraw its first-generation COVID-19 vaccine candidate and focus on collaborating with GSK to develop second-generation mRNA vaccine technology instead, the Germany-based...

FILE PHOTO: A volunteer receives a dose of CureVac vaccine or a placebo during a study by the German biotech firm CureVac as part of a testing for a new vaccine against the coronavirus disease (COVID-19),...

The U.K. government announced Friday that it plans to work with a German biopharmaceutical company to develop vaccines targeting emerging variants of COVID-19 as public health officials call for new tools...